This randomized pilot trial enrolled 23 patients in each arm (one arm being treated with LHRH agonist and the other treated with LHRH antagonist: degarelix). They found six cardiovascular events within the first six months of follow-up in the LHRH agonist arm.
In addition they found the FSH levels decreased significantly in the LHRH-agonist arm compared to degarelix. In addition those with lower FSH decreases in the LHRH-agonist arm (p<0.001) had a 50% increase in the probability of cardiovascular morbidity.
Although this is a small pilot study, there are important implications of the role of FSH and cardiovascular morbidity. With further work in this area there may be increasing evidence against the use of LHRH-agonists resulting in an improved morbidity profile for patients with advanced prostate cancer by using LHRH-antagonists.
Presented By: Jehonathan H. Pinthus, MD, PhD, FRCSC
Written By: Janet Baack Kukreja (@janetkukreja), MD, MPH, Urologic Oncology Fellow, Department of Urology, UT MD Anderson Cancer Center, Houston, TX, Ashish M. Kamat, MD, MBBS, FACS, Wayne B. Duddlesten Professor, Department of Urology, UT MD Anderson Cancer Center, Houston TX
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA